These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 21476818)

  • 1. Interpreting patient-reported outcome results: US FDA guidance and emerging methods.
    McLeod LD; Coon CD; Martin SA; Fehnel SE; Hays RD
    Expert Rev Pharmacoecon Outcomes Res; 2011 Apr; 11(2):163-9. PubMed ID: 21476818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methods for interpreting change over time in patient-reported outcome measures.
    Wyrwich KW; Norquist JM; Lenderking WR; Acaster S;
    Qual Life Res; 2013 Apr; 22(3):475-83. PubMed ID: 22528240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential of patient-reported outcomes as nonprimary endpoints in clinical trials.
    Gnanasakthy A; Lewis S; Clark M; Mordin M; DeMuro C
    Health Qual Life Outcomes; 2013 May; 11():83. PubMed ID: 23675876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. US FDA patient-reported outcome guidance: great expectations and unintended consequences.
    Fehnel S; DeMuro C; McLeod L; Coon C; Gnanasakthy A
    Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):441-6. PubMed ID: 23977972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance.
    ; ;
    Health Qual Life Outcomes; 2006 Oct; 4():79. PubMed ID: 17034633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient Reported Outcome (PRO) assessment in epilepsy: a review of epilepsy-specific PROs according to the Food and Drug Administration (FDA) regulatory requirements.
    Nixon A; Kerr C; Breheny K; Wild D
    Health Qual Life Outcomes; 2013 Mar; 11():38. PubMed ID: 23497117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-Reported Outcomes in Chronic Heart Failure: Applicability for Regulatory Approval.
    Psotka MA; von Maltzahn R; Anatchkova M; Agodoa I; Chau D; Malik FI; Patrick DL; Spertus JA; Wiklund I; Teerlink JR
    JACC Heart Fail; 2016 Oct; 4(10):791-804. PubMed ID: 27395351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001.
    Acquadro C; Berzon R; Dubois D; Leidy NK; Marquis P; Revicki D; Rothman M;
    Value Health; 2003; 6(5):522-31. PubMed ID: 14627058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-reported outcomes supporting anticancer product approvals.
    Rock EP; Kennedy DL; Furness MH; Pierce WF; Pazdur R; Burke LB
    J Clin Oncol; 2007 Nov; 25(32):5094-9. PubMed ID: 17991927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of patient-reported outcome labels in the United States: 2006 to 2010.
    Gnanasakthy A; Mordin M; Clark M; DeMuro C; Fehnel S; Copley-Merriman C
    Value Health; 2012 May; 15(3):437-42. PubMed ID: 22583453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report.
    Coons SJ; Gwaltney CJ; Hays RD; Lundy JJ; Sloan JA; Revicki DA; Lenderking WR; Cella D; Basch E;
    Value Health; 2009 Jun; 12(4):419-29. PubMed ID: 19900250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond the FDA PRO guidance: steps toward integrating meaningful patient-reported outcomes into regulatory trials and US drug labels.
    Basch E
    Value Health; 2012 May; 15(3):401-3. PubMed ID: 22583448
    [No Abstract]   [Full Text] [Related]  

  • 13. Documenting the rationale and psychometric characteristics of patient reported outcomes for labeling and promotional claims: the PRO Evidence Dossier.
    Revicki DA; Gnanasakthy A; Weinfurt K
    Qual Life Res; 2007 May; 16(4):717-23. PubMed ID: 17268927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of PRO label claims granted by the FDA as compared to the EMA (2006-2010).
    DeMuro C; Clark M; Doward L; Evans E; Mordin M; Gnanasakthy A
    Value Health; 2013 Dec; 16(8):1150-5. PubMed ID: 24326168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How a well-grounded minimal important difference can enhance transparency of labelling claims and improve interpretation of a patient reported outcome measure.
    Brozek JL; Guyatt GH; Schünemann HJ
    Health Qual Life Outcomes; 2006 Sep; 4():69. PubMed ID: 17005037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency.
    Bottomley A; Jones D; Claassens L
    Eur J Cancer; 2009 Feb; 45(3):347-53. PubMed ID: 19013787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pain palliation measurement in cancer clinical trials: the US Food and Drug Administration perspective.
    Basch E; Trentacosti AM; Burke LB; Kwitkowski V; Kane RC; Autio KA; Papadopoulos E; Stansbury JP; Kluetz PG; Smith H; Justice R; Pazdur R
    Cancer; 2014 Mar; 120(5):761-7. PubMed ID: 24375398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels.
    Willke RJ; Burke LB; Erickson P
    Control Clin Trials; 2004 Dec; 25(6):535-52. PubMed ID: 15588741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016).
    Gnanasakthy A; Barrett A; Evans E; D'Alessio D; Romano CD
    Value Health; 2019 Feb; 22(2):203-209. PubMed ID: 30711065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The FDA guidance for industry on PROs: the point of view of a pharmaceutical company.
    Arpinelli F; Bamfi F
    Health Qual Life Outcomes; 2006 Oct; 4():85. PubMed ID: 17076891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.